Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1

Patients with EGFR-mutant lung adenocarcinomas (LUADs) who initially respond to first-generation TKIs develop resistance to these drugs. A combination of the irreversible TKI afatinib and the EGFR antibody cetuximab can be used to overcome resistance to first-generation TKIs; however, resistance to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Pirazzoli, Valentina, Nebhan, Caroline, Song, Xiaoling, Wurtz, Anna, Walther, Zenta, Cai, Guoping, Zhao, Zhongming, Jia, Peilin, de Stanchina, Elisa, Shapiro, Erik M., Gale, Molly, Yin, Ruonan, Horn, Leora, Carbone, David P., Stephens, Philip J, Miller, Vincent, Gettinger, Scott, Pao, William, Politi, Katerina
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4074596/
https://ncbi.nlm.nih.gov/pubmed/24813888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2014.04.014
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars